View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsIndivior 향후 성장Future 기준 점검 4/6현재 Indivior 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.핵심 정보40.4%이익 성장률42.37%EPS 성장률Pharmaceuticals 이익 성장23.7%매출 성장률11.9%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트06 Jun 2023최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 23Indivior PLC Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like FentanylIndivior PLC announced that the U.S. Food and Drug Administration (FDA) approved OPVEE® (nalmefene) nasal spray for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression. OPVEE contains nalmefene, an opioid receptor antagonist that provides fast onset and long duration reversal of opioid-induced respiratory depression, which is the primary cause of opioid overdose injury and death. OPVEE was designed to address the challenges of today's opioid crisis. OPVEE was approved via the 505(b)(2) pathway. In a first of its kind pharmacodynamic study (NCT04828005) in 61 opioid-experienced, non-dependent subjects, the effect of 2.7 mg OPVEE was assessed on remifentanil-induced respiratory depression. Following OPVEE administration, the time to onset of reversal of respiratory depression was observed between 2.5 to 5 minutes and full recovery of respiratory drive was manifested as early as 5 minutes after OPVEE administration. The duration of action of nalmefene is as long as most opioids, including fentanyl. These attributes are well-suited to address the challenges of today's opioid overdose crisis. The speed of action, long duration, and high potency of fentanyl and other synthetic opioids are driving unprecedented overdose deaths across a broader range of ages, and they are now a leading cause of death for people ages 18 to 45.5 For each opioid-induced fatality, it has been estimated that there are an additional 6.4-8.4 non-fatal overdoses that can lead to long-term physical and mental disability. A federally funded contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services, for up to $10.8 million, combined with a $7.4 million U01 "grand opportunities in medications development" grant received from the National Institute on Drug Abuse (NIDA), supported the development of OPVEE. The contract (number HHSO100201800029C) with BARDA was intended to develop OPVEE for reversal of opioid overdoses in the community and as a medical countermeasure and reversal agent in the event of a chemical attack using synthetic opioids. OPVEE is expected to be in the market in Fourth Quarter of 2023. Indivior added OPVEE to its portfolio with the acquisition of Opiant Pharmaceuticals Inc., which closed March 2, 2023. As previously indicated, Indivior believes the clinical profile of OPVEE supports the potential for this treatment to deliver annual net revenue of $150 million to $250 million, with expected earnings accretion from the Opiant acquisition after the second full year of launch of OPVEE.공시 • Feb 17Indivior PLC Announces Board and Committee ChangesIndivior PLC announced that Juliet Thompson has been appointed as Senior Independent Director with effect from October 1, 2023. Juliet has been a Non-Executive Director since March 2021 and is the Chair of the Audit Committee and a member of the Nomination & Governance Committee. The Company further announces that Jo Le Couilliard has been appointed as Chair of the Remuneration Committee also with effect from October 1, 2023. Jo has been a Non-Executive Director since March 2021 and is a member of the Audit and Remuneration Committees. This announcement follows the Company's previous announcement on October 13, 2022 that Daniel J. Phelan, current Senior Independent Director and Chair of the Remuneration Committee, will stand down from the Board on September 30, 2022 having served as a Director for nine years.공시 • Jan 12Indivior PLC to Report Q4, 2022 Results on Feb 16, 2023Indivior PLC announced that they will report Q4, 2022 results at 2:00 AM, US Eastern Standard Time on Feb 16, 2023공시 • Nov 28Reckitt Benckiser Group Submits Claim against Indivior PLCIndivior PLC announced it has been made aware that a claim was submitted to the Commercial Court in London by Reckitt Benckiser Group plc ('RB') against the company on November 13, 2020 pursuant to an indemnity contained in the Demerger Agreement entered into between RB and the Company on November 17, 2014. The amount claimed under the submission is £1,073,622.580.51. The claim has not been served on the company and the company does not have any further details at this time. The company will assess with its advisors the background and merits to the case and will provide an update in due course.공시 • Nov 21+ 1 more updateIndivior PLC Announces the Appointment of Ryan Preblick as Executive DirectorThe Board of Directors of Indivior PLC announced the appointment of Ryan Preblick as Executive Director with immediate effect. Ryan has been serving as Interim Chief Financial Officer since June 2020 and has been in financial leadership roles since joining Indivior in 2012. Prior to his appointment as Interim Chief Financial Officer in June 2020, Ryan was Senior Vice President, Global Financial Planning and Analysis Commercial Operations. This role included overseeing all key financial management, analysis and reporting elements of the Group's global business. Prior to that, Ryan was Vice President, US Finance with responsibility overseeing all financial areas of the US business, the Group's large business, including management, planning, analysis and reporting, government pricing and managed care contracting operations. Ryan started his career in corporate finance at Honeywell International and then spent twelve years at Altria Company (including Philip Morris USA) in finance leadership roles of increasing responsibility working with Treasury, Financial Planning & Analysis, Market Analytics, Supply Chain and Brand Decision Support. Ryan holds a BS in Finance from Penn State University and an MBA from the University of Richmond.공시 • Nov 19Indivior PLC Announces Executive ChangesIndivior PLC announced the appointment of Graham Hetherington as Chair of the Board with immediate effect. Graham's appointment was approved by the Board and follows a succession process undertaken by the Nomination & Governance Committee and led by Lorna Parker, Chair of the Nomination & Governance Committee. Graham will step down as Chair of the Audit Committee. Daniel Tassé will remain the Senior Independent Director and will be appointed Chair of the Audit Committee, effective immediately. Daniel has been a member of the Audit Committee since the Company listed in 2014 and served as Chair of the Audit Committee between July 2019 and March 2020. Graham will be appointed as a member of the Nomination & Governance Committee and will remain a member of the Audit and Remuneration Committees. The Board also intends to undertake a search to identify an additional independent Non-Executive Director with recent and relevant financial experience.공시 • Sep 30Indivior PLC to Report Q3, 2020 Results on Oct 29, 2020Indivior PLC announced that they will report Q3, 2020 results on Oct 29, 2020공시 • Sep 21Indivior PLC(LSE:INDV) dropped from FTSE All-Small Index (GBP)Indivior PLC(LSE:INDV) dropped from FTSE All-Small Index (GBP)공시 • Jul 18Indivior PLC to Report Q2, 2020 Results on Jul 30, 2020Indivior PLC announced that they will report Q2, 2020 results at 2:00 AM, US Eastern Standard Time on Jul 30, 2020공시 • Jun 29Indivior PLC Announces CEO ChangesIndivior PLC announced that effective June 29, 2020, the Board of Directors has appointed Mark Crossley as Chief Executive Officer. Shaun Thaxter, in mutual agreement with the Board, is stepping down as Chief Executive Officer and Executive Director. Mr. Crossley has been Chief Financial and Operations Officer (CFOO) and Executive Director of Indivior since February 2017. He was previously Chief Strategy Officer from 2014-2017 and served as Finance Director where he led the demerger of Indivior from its former parent. Prior to joining Indivior in 2012, Mark spent thirteen years at Procter & Gamble in various finance leadership positions and eight years as an officer in the United States Coast Guard.이익 및 매출 성장 예측DB:2IVA - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20251,287307279285212/31/20241,134250157213412/31/20231,018169-381443/31/2023947-502335N/A12/31/2022901-53-9-4N/A9/30/2022883166176181N/A6/30/2022838152160145N/A3/31/2022818166175189N/A12/31/2021791205339353N/A9/30/2021753156101115N/A6/30/202172513981115N/A3/31/2021674953942N/A12/31/2020647-148-197-193N/A9/30/2020595-190-84-82N/A6/30/2020634-152-70-69N/A3/31/2020700-95-131-130N/A12/31/2019785134148151N/A9/30/2019889213217200N/A6/30/2019935254281275N/A3/31/2019988248401413N/A12/31/20181,005275299303N/A9/30/20181,033106247276N/A6/30/20181,06467171210N/A3/31/20181,08371231260N/A12/31/20171,09358252295N/A9/30/20171,087281310360N/A6/30/20171,08081371409N/A3/31/20171,06565331370N/A12/31/20161,05835N/A407N/A9/30/20161,047-6N/A326N/A6/30/20161,028191N/A283N/A3/31/20161,021201N/A252N/A12/31/20151,014228N/A320N/A9/30/20151,037268N/A300N/A6/30/20151,058314N/A369N/A3/31/20151,085361N/A530N/A12/31/20141,115403N/A440N/A9/30/20141,147443N/A572N/A12/31/20131,216489N/A791N/A12/31/20121,339607N/A866N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 2IVA 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(0.2%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: 2IVA (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: 2IVA 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: 2IVA 의 수익(연간 11.9%)이 German 시장(연간 6.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 2IVA 의 수익(연간 11.9%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 2IVA의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/06/13 20:05종가2023/05/29 00:00수익2023/03/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Indivior Pharmaceuticals, Inc.는 9명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Graham Glyn ParryBofA Global ResearchChase KnickerbockerCraig-Hallum Capital Group LLCBrandon FolkesH.C. Wainwright & Co.6명의 분석가 더 보기
공시 • May 23Indivior PLC Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like FentanylIndivior PLC announced that the U.S. Food and Drug Administration (FDA) approved OPVEE® (nalmefene) nasal spray for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression. OPVEE contains nalmefene, an opioid receptor antagonist that provides fast onset and long duration reversal of opioid-induced respiratory depression, which is the primary cause of opioid overdose injury and death. OPVEE was designed to address the challenges of today's opioid crisis. OPVEE was approved via the 505(b)(2) pathway. In a first of its kind pharmacodynamic study (NCT04828005) in 61 opioid-experienced, non-dependent subjects, the effect of 2.7 mg OPVEE was assessed on remifentanil-induced respiratory depression. Following OPVEE administration, the time to onset of reversal of respiratory depression was observed between 2.5 to 5 minutes and full recovery of respiratory drive was manifested as early as 5 minutes after OPVEE administration. The duration of action of nalmefene is as long as most opioids, including fentanyl. These attributes are well-suited to address the challenges of today's opioid overdose crisis. The speed of action, long duration, and high potency of fentanyl and other synthetic opioids are driving unprecedented overdose deaths across a broader range of ages, and they are now a leading cause of death for people ages 18 to 45.5 For each opioid-induced fatality, it has been estimated that there are an additional 6.4-8.4 non-fatal overdoses that can lead to long-term physical and mental disability. A federally funded contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services, for up to $10.8 million, combined with a $7.4 million U01 "grand opportunities in medications development" grant received from the National Institute on Drug Abuse (NIDA), supported the development of OPVEE. The contract (number HHSO100201800029C) with BARDA was intended to develop OPVEE for reversal of opioid overdoses in the community and as a medical countermeasure and reversal agent in the event of a chemical attack using synthetic opioids. OPVEE is expected to be in the market in Fourth Quarter of 2023. Indivior added OPVEE to its portfolio with the acquisition of Opiant Pharmaceuticals Inc., which closed March 2, 2023. As previously indicated, Indivior believes the clinical profile of OPVEE supports the potential for this treatment to deliver annual net revenue of $150 million to $250 million, with expected earnings accretion from the Opiant acquisition after the second full year of launch of OPVEE.
공시 • Feb 17Indivior PLC Announces Board and Committee ChangesIndivior PLC announced that Juliet Thompson has been appointed as Senior Independent Director with effect from October 1, 2023. Juliet has been a Non-Executive Director since March 2021 and is the Chair of the Audit Committee and a member of the Nomination & Governance Committee. The Company further announces that Jo Le Couilliard has been appointed as Chair of the Remuneration Committee also with effect from October 1, 2023. Jo has been a Non-Executive Director since March 2021 and is a member of the Audit and Remuneration Committees. This announcement follows the Company's previous announcement on October 13, 2022 that Daniel J. Phelan, current Senior Independent Director and Chair of the Remuneration Committee, will stand down from the Board on September 30, 2022 having served as a Director for nine years.
공시 • Jan 12Indivior PLC to Report Q4, 2022 Results on Feb 16, 2023Indivior PLC announced that they will report Q4, 2022 results at 2:00 AM, US Eastern Standard Time on Feb 16, 2023
공시 • Nov 28Reckitt Benckiser Group Submits Claim against Indivior PLCIndivior PLC announced it has been made aware that a claim was submitted to the Commercial Court in London by Reckitt Benckiser Group plc ('RB') against the company on November 13, 2020 pursuant to an indemnity contained in the Demerger Agreement entered into between RB and the Company on November 17, 2014. The amount claimed under the submission is £1,073,622.580.51. The claim has not been served on the company and the company does not have any further details at this time. The company will assess with its advisors the background and merits to the case and will provide an update in due course.
공시 • Nov 21+ 1 more updateIndivior PLC Announces the Appointment of Ryan Preblick as Executive DirectorThe Board of Directors of Indivior PLC announced the appointment of Ryan Preblick as Executive Director with immediate effect. Ryan has been serving as Interim Chief Financial Officer since June 2020 and has been in financial leadership roles since joining Indivior in 2012. Prior to his appointment as Interim Chief Financial Officer in June 2020, Ryan was Senior Vice President, Global Financial Planning and Analysis Commercial Operations. This role included overseeing all key financial management, analysis and reporting elements of the Group's global business. Prior to that, Ryan was Vice President, US Finance with responsibility overseeing all financial areas of the US business, the Group's large business, including management, planning, analysis and reporting, government pricing and managed care contracting operations. Ryan started his career in corporate finance at Honeywell International and then spent twelve years at Altria Company (including Philip Morris USA) in finance leadership roles of increasing responsibility working with Treasury, Financial Planning & Analysis, Market Analytics, Supply Chain and Brand Decision Support. Ryan holds a BS in Finance from Penn State University and an MBA from the University of Richmond.
공시 • Nov 19Indivior PLC Announces Executive ChangesIndivior PLC announced the appointment of Graham Hetherington as Chair of the Board with immediate effect. Graham's appointment was approved by the Board and follows a succession process undertaken by the Nomination & Governance Committee and led by Lorna Parker, Chair of the Nomination & Governance Committee. Graham will step down as Chair of the Audit Committee. Daniel Tassé will remain the Senior Independent Director and will be appointed Chair of the Audit Committee, effective immediately. Daniel has been a member of the Audit Committee since the Company listed in 2014 and served as Chair of the Audit Committee between July 2019 and March 2020. Graham will be appointed as a member of the Nomination & Governance Committee and will remain a member of the Audit and Remuneration Committees. The Board also intends to undertake a search to identify an additional independent Non-Executive Director with recent and relevant financial experience.
공시 • Sep 30Indivior PLC to Report Q3, 2020 Results on Oct 29, 2020Indivior PLC announced that they will report Q3, 2020 results on Oct 29, 2020
공시 • Sep 21Indivior PLC(LSE:INDV) dropped from FTSE All-Small Index (GBP)Indivior PLC(LSE:INDV) dropped from FTSE All-Small Index (GBP)
공시 • Jul 18Indivior PLC to Report Q2, 2020 Results on Jul 30, 2020Indivior PLC announced that they will report Q2, 2020 results at 2:00 AM, US Eastern Standard Time on Jul 30, 2020
공시 • Jun 29Indivior PLC Announces CEO ChangesIndivior PLC announced that effective June 29, 2020, the Board of Directors has appointed Mark Crossley as Chief Executive Officer. Shaun Thaxter, in mutual agreement with the Board, is stepping down as Chief Executive Officer and Executive Director. Mr. Crossley has been Chief Financial and Operations Officer (CFOO) and Executive Director of Indivior since February 2017. He was previously Chief Strategy Officer from 2014-2017 and served as Finance Director where he led the demerger of Indivior from its former parent. Prior to joining Indivior in 2012, Mark spent thirteen years at Procter & Gamble in various finance leadership positions and eight years as an officer in the United States Coast Guard.